HC Wainwright Boosts FY2026 Earnings Estimate for Galectin Therapeutics

Research analysts lift projections for the biotech company's future performance

Apr. 3, 2026 at 11:23am

Got story updates? Submit your updates here. ›

An extreme close-up of highly detailed, interlocking metal components and machinery in shades of steel grey, bronze, and chrome, conceptually representing the complex financial systems and institutional infrastructure powering the biotech industry's growth.Detailed, industrial imagery evokes the complex financial systems and institutional infrastructure powering the biotech industry's growth.Norcross Today

Analysts at HC Wainwright have increased their FY2026 earnings estimates for Galectin Therapeutics Inc. (NASDAQ:GALT), forecasting the company will post earnings of ($0.31) per share, up from their prior estimate of ($0.41) per share. The firm maintains a 'Buy' rating and $11.00 price target on the stock.

Why it matters

This revised earnings outlook suggests improved financial prospects for Galectin Therapeutics, a clinical-stage biotech focused on developing novel therapies for fibrotic, inflammatory and malignant diseases. The stock's performance and future growth potential are closely watched by investors in the healthcare and biotech sectors.

The details

In a note to investors on Tuesday, March 31st, HC Wainwright analyst M. Keller lifted the firm's FY2026 earnings estimates for Galectin Therapeutics. The consensus estimate for the company's current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin's FY2027 earnings at ($0.33) per share.

  • On Tuesday, March 31st, HC Wainwright issued the revised FY2026 earnings estimates for Galectin Therapeutics.

The players

HC Wainwright

A research and investment banking firm that covers Galectin Therapeutics and has issued updated earnings estimates for the company.

M. Keller

The HC Wainwright analyst who authored the note with the revised FY2026 earnings projections for Galectin Therapeutics.

Galectin Therapeutics Inc.

A clinical-stage biotechnology company focused on developing novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

The takeaway

The improved earnings outlook from a respected research firm like HC Wainwright suggests Galectin Therapeutics may be making progress in advancing its pipeline of novel therapies, which could translate to stronger financial performance in the coming years. However, the stock still faces challenges and uncertainty, underscoring the need for continued monitoring of the company's developments.